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Abstract: The crystal structures of four
dipeptides that contain the stereochemi-
cally constrained -amino acid residue
gabapentin (1-(aminomethyl)cyclohexa-
neacetic acid Gpn) are described. The
molecular conformation of Piv-Pro-
Gpn-OH (1), reveals a -turn mimetic
conformation, stabilized by a ten atom
CH ¥ ¥ ¥O hydrogen bond between the
Piv CO group and the pro S hydrogen of
the Gpn CH2CO group. The peptides
Boc-Gly-Gpn-OH (2), Boc-Aib-Gpn-
OH (3), and Boc-Aib-Gpn-OMe (4)
form compact, folded structures, in
which a distinct reversal of polypeptide
chain direction is observed. In all cases,
the Gpn residue adopts a gauche,gauche
(g,g) conformation about the C C (1)
and CC (2) bonds. Two distinct Gpn
conformational families are observed. In
peptides 1 and 3, the average backbone
torsion angle values for the Gpn residue
are  98, 162, 273, and
 79, while in peptide 2 and 4 the
average values are 103, 1
46, 249, and 92. In the
case of 1 and 3, an intramolecular nine-
membered OH ¥ ¥ ¥O hydrogen bond is
formed between the CO of the preced-
ing residue and the terminal carboxylic
acid OH group. All four  ±  dipeptide
sequences yield compact folded back-
bone conformations; this suggests that
the Gpn residue may be employed
successfully in the design of novel folded
structures.
Keywords: amino acids ¥ beta-turn
mimetics ¥ hydrogen bonds ¥
peptides ¥ structure elucidation
Introduction
Polypeptide chain reversals nucleated by two contiguous
residues, -turns, are widely found in proteins,[1] and are
commonly observed structural feature in biologically active
peptides.[2] -Turns were originally recognized in an attempt
to stereochemically characterize the intramolecular hydrogen
bonded conformations of ™three linked peptide units∫.[3]
Canonical -turns in polypeptides, derived from -amino
acid residues, are stabilized by 4 1 (C10) hydrogen bonds
between COi and Ni3H groups. The residues i 1 and i 2
form the turning fulcrum of the polypeptide chain with the
torsion angles i1, i1, i2, and i2 , each varying for
different specific -turn types.[4] The area of peptidomimetic
design has seen considerable activity directed towards the
synthesis of -turn mimetics.[5] The impetus for these efforts
derives from the role of -turns as determinants of three-
dimensional structure in a large number of pharmacologically
important peptides.[6] During the investigations into the
conformations of hybrid peptide sequences, that contain both
- and -amino acids, we observed an interesting CH ¥ ¥ ¥O
hydrogen-bond-stabilized chain reversal in the peptide Piv--
Pro--Abu-NHMe (-Abu, -aminobutyric acid); this struc-
ture was determined ab initio from powder X-ray diffraction
data.[7] In seeking to establish the generality of this conforma-
tional feature, and in order to explore the possibility of
generating new -turn mimetics, we investigated the struc-
tures of peptides that contain the conformationally con-
strained, achiral -amino acid residue, 1-(aminomethyl)cyclo-
hexaneacetic acid (gabapentin (Gpn) Figure 1a). The amino
acid gabapentin is a widely used anti-epileptic drug, which
exists in solution as mixtures of two interconverting con-
Figure 1. a) Schematic representation of gabapentin (Gpn) b) The param-
eters used to define the dihedral angles.[19e,f]
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formations that correspond to
the two possible chair forms.[8]
In crystals, the conformation
with the aminomethyl group
axial has been characterized.[9]
Gpn is a ,-dialkylated -ami-
no acid residue with geminal
substitutents at C ; this restricts
the range of accessible confor-
mations about the torsion an-
gles 1 and 2 (Figure 1b). Here,
we describe the crystal struc-
ture of four peptides that con-
tain the Gpn residues: Piv--
Pro-Gpn-OH (1), Boc-Gly-
Gpn-OH (2), Boc-Aib-Gpn-
OH (3), and Boc-Aib-Gpn-
OMe (4) (Aib, -aminoisobu-
tyric acid). We illustrate the
conformational similarities of
the chain reversals observed in
specific  ±  sequences to the
conventional -turns observed
in  ± sequences.
Results and Discussion
Figure 2 shows the molecular
conformation of peptides 1 to 4
in single crystals. The crystallo-
graphic data are given in Ta-
ble 1. Table 2 summarizes the
backbone dihedral angles,
which serve as a descriptor of
the fold for the polypeptide
chain. Table 3 lists the observed
intra- and intermolecular hy-
drogen bonds, while a view of
the packing motif in the four
structures is illustrated in Fig-
ure 3. In all four peptides, it is
clear that the  ±  sequence
results in a backbone chain
reversal. This is clearly a con-
sequence of the gauche,gauche
(g,g) conformation adopted
about the C C and CC
bonds of the Gpn residue. In
all four peptides, the cyclohex-
ane ring adopts an almost per-
fect chair conformation. In pep-
tides 1 and 3 the carboxymethyl
substitutent occupies an axial
position, while in peptides 2
and 4 the aminomethyl group
takes up the axial orientation.
Clearly, both possible chair
conformations are readily ac-
Table 1. Crystal and diffraction parameters.
1 2 3 4
formula C19H32N2O4 ¥H2O C16H28N2O5 C18H32N2O5 C19H34N2O5
crystal habit clear clear clear white
crystal size [mm] 0.23 0.19 0.1 0.92 0.76 0.56 0.86 0.5 0.08 1.26 0.58 0.26
crystallizing solvent ethyl acetate methanol/water methanol/water methanol
space group P212121 P1≈ Pbca P21/c
a [ä] 9.7899(9) 6.951(2) 9.718(2) 10.509(5)
b [ä] 23.854(2) 10.785(3) 12.379(3) 10.547(5)
c [ä] 8.9726(8) 12.927(4) 33.479(9) 20.240(9)
 [] 90.0 78.556(5) 90.0 90.0
 [] 90.0 79.095(5) 90.0 96.022(7)
 [] 90.0 84.330(5) 90.0 90.0
Volume [ä3] 2095.3(3) 930.8(5) 4027.5(17) 2230.9(18)
Z 4 2 8 4
molecules/asymmetric unit 1 1 1 1
co-crystallized solvent one water none none none
Mr 370.48 328.40 356.46 370.48
cald [gcm3] 1.174 1.172 1.176 1.103
F (000) 808 356 1552 808
T [C] 21 21 21 21
2max [] 54.08 54.36 53.8 53.72
measured reflections 15776 9862 28440 16121
Rint 0.0166 0.1104 0.1032 0.0369
independent reflections 4178 3730 4128 4381
observed reflections [F  4(F) ] 3756 3147 3012 3199
final R [%] 4.8 5.23 6.06 7.63
final wR2 [%] 13.32 14.17 11.78 21.45
goodness of fit 1.048 1.061 1.03 1.025
max/min[e ä3] 0.47/ 0.20 0.26/ 0.29 0.16/ 0.14 0.65/ 0.41
restraints/parameters 0/335 0/320 0/354 1/359
data to parameter ratio 11.2:1 9.8:1 8.5:1 8.9:1
Figure 2. Molecular conformation of a) Piv-Pro-Gpn-OH (1), b) Boc-Gly-Gpn-OH (2), c) Boc-Aib-Gpn-OH
(3), d) Boc-Aib-Gpn-OMe (4) in crystals.
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commodated in the observed peptide structures. Crystallo-
graphic and NMR investigations on the free amino acid Gpn
and several of its derivatives suggests that the two possible
chair forms differ only marginally in energy, and undergo
rapid interconversion in solution.[8c] .
Structural features in Gpn peptides
peptide 1: Piv--Pro-Gpn-OH adopts a folded conformation
stabilized by two potential intramolecular hydrogen bonds:
Piv CO ¥ ¥ ¥HC Gpn and Pro CO ¥ ¥ ¥HO Gpn. The
relevant hydrogen-bond parameters are listed in Table 3.
These values fall well within the range observed for poten-
tially favorable CH ¥ ¥ ¥O interactions.[10] The observed
CH ¥ ¥ ¥O interaction results in the formation of a ten-atom
hydrogen-bonded ring, reminiscent of that observed in
peptide -turns, a feature previously detected in the peptide
Piv-Pro--Abu-NHMe by powder diffraction data. The sec-
ond intramolecular nine-membered OH ¥ ¥ ¥O hydrogen
bond is formed between the Pro CO group and OH group
of the terminal carboxylic acid
moiety. This results in the adop-
tion of the unusual anti confor-
mation by the terminal carbox-
ylic acid group. Theoretical cal-
culations have estimated the
energy difference between the
syn and anti conformation of
carboxylic acids to be about 4±8
kcalmol1; this results in the
predominant population of syn
forms in solution and in the
solid state.[11] The -Pro residue
adopts a semi-extended confor-
mation (56.9, 
145.7), which is similar to that
observed for the i 1 position
in type II -turns in all -amino
acid structures.
In crystals, a lone water mol-
ecule bridges symmetry related
molecules of the peptides, by
forming hydrogen bonds to
Gpn NH, Piv CO; and Gpn
CO groups. The structure of
peptide 1 may be considered as
a formal analogue of a conven-
tional -turn, in which a ten-
atom CH ¥ ¥ ¥O hydrogen bond
acts as a mimic for a ten-atom NH ¥ ¥ ¥O (4 1) hydrogen
bond. Notably, hydration of the central peptide unit, as seen in
1, is also a feature commonly seen in -turns in protein
structures.[12]
Peptide 2 : In Boc-Gly-Gpn-OH, a single intramolecular
seven-membered hydrogen bond between the Gpn NH and
CO groups is observed. The Gly residue adopts a conforma-
tion in the helical region of , space, with appreciable
distortion of both dihedral angles from ideal values. Aview of
the crystal packing is shown in Figure 3. Notably, the CO
group of the Gly residue is not involved in any hydrogen bond.
Peptide 3 : In Boc-Aib-Gpn-OH, a single intramolecular nine-
membered OH ¥ ¥ ¥O hydrogen bond is observed between the
Aib CO moiety and the carboxylic acid OH group of Gpn.
Inspection of the dihedral angles for the Gpn residue
(Table 2) reveals a conformation almost identical to that
observed in Piv--Pro-Gpn-OH (1). However, in contrast to
peptide 1, the Aib residue in 3 adopts , values characteristic
Table 2. Backbone torsion angles [][a,b] in  ±  peptides.
Peptide 1 1 1 2 1 2 2 2 Axial group
1  56.9 145.7 180 92.9  66.7  70.7 84.6 ± carboxymethyl
2  80.7  7.1  176.9  103.7  44.9  48.7  94.3 ± aminomethyl
3 55.4 46.2 174.0 103.9  57.3  75.5 73.5 ± carboxymethyl
4  68.5  25.3  178.2  102.1  48.2  50.3  90.0 170.6 aminomethyl
[a] For -residue nomenclature see ref. [4c], for -residue nomenclature see ref. [19ef]. [b] Peptides 2 ± 4 are achiral and crystallize in centrosymmetric space
groups that accommodate molecules with enantiomeric conformations. For convenience, the sign of the torsion angles listed has been chosen to correspond to
the same signs for 1 and 2 as observed for the chiral peptide 1. The estimated standard deviation is 0.2.
Table 3. Hydrogen bonds in peptides 1 ± 4.[a]
Donor Acceptor D ¥¥¥A [ä] H ¥¥¥A [ä] CO ¥¥¥H [] CO¥¥¥D [] DH ¥¥¥A []
peptide 1
intramolecular
O3 O1 2.614 1.917 127.94 128.49 165.88
C2A O0 3.554 2.571 127.98 130.76 169.63
intermolecular
N2 O1w 2.865 1.972 166.11
O1w O2[b] 2.908 2.078 155.60 158.87 163.08
O1w O0[c] 2.876 1.980 144.60 142.01 167.29
peptide 2
intramolecular
N2 O2 2.928 2.263 102.22 91.68 136.13
intermolecular
N1 O2[d] 3.024 2.251 169.12 165.97 163.81
O3 O0[e] 2.643 1.734 140.30 143.24 170.93
peptide 3
intramolecular
O3 O1 2.593 1.657 119.59 123.47 169.11
intermolecular
N1 O1[f] 3.143 2.331 147.69 149.83 159.94
N2 O3[f] 2.933 2.078 127.82 124.06 163.22
peptide 4
intramolecular
N2 O2 2.957 2.339 100.72 91.3 129.08
intermolecular
N1 O1[g] 2.946 2.119 140.02 139.4 174.75
[a] The standard deviations in bond lengths are approximately 0.004 ä and those of bond angles are
approximately 0.2. [b] Symmetry related by x 1, y, z. [c] Symmetry related by x 1/2, y, z 1/2.
[d] Symmetry related by x, y 1, z. [e] Symmetry related by x 1, y, z. [f] Symmetry related by x 1/2,
y 1/2, z. [g] Symmetry related by x, y 1/2, z 3/2.
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of a helical conformation. This results in an altered orienta-
tion of the N-terminal urethane group, which leads to the
absence of the CH ¥ ¥ ¥O interaction noted in peptide 1. In
crystals, the carboxyl group of the terminal carboxylic acid is
not involved in any strong hydrogen-bonding interaction. This
may be in contrast to the situation in peptide 1, in which both
oxygen atoms of the terminal carboxylic acid group partic-
ipate in hydrogen bond interactions.
Peptide 4 : The observed molecular conformation in Boc-Aib-
Gpn-OMe (4) is very similar to that observed in Boc-Gly-
Gpn-OH (2). A single intramolecular seven-membered
NH ¥ ¥ ¥O hydrogen bond that involves the Gpn NH and
CO groups is observed. The similarity between peptides 2 and
4 is also clearly evident upon comparison of observed
backbone torsion angles (Table 2). In the packing motif
shown in Figure 3, all the hydrogen bond donors and accept-
ors are paired in intermolecular hydrogen bonds. In this
conformation, the distance between the O atom of the Boc
group, and the C atom of the terminal ester methyl group is
6.618 ä; this is indicative of a sharp reversal of chain
direction. In -peptides, the C(i) to C(i 3) distance of
7.0 ä characterizes chain reversals nucleated by two resi-
dues, of which -turns, with 4 1 intramolecular hydrogen
bonds, are most abundant.[13]
Conformational characterization of  ±  chain reversals :
Figure 4a shows a superposition of the conformations detect-
ed in peptides Piv--Pro--Abu-NHMe[7] and Piv--Pro-Gpn-
OH. It is clearly seen that the ten-atom CH ¥ ¥ ¥O hydrogen-
bonded rings superpose well, with the important difference
that the central peptide unit linking the Pro and -amino acid
residue adopts different orientations, which corresponds to
simultaneous rotations about the torsion angles, Pro and
Abu/Gpn. Interconversion between different -turn types,
type I and type II, in  ± sequences can occur by concerted
motion involving flipping of the central peptide unit.[14] Thus,
the two CH ¥ ¥ ¥O stabilized turn conformations observed in
the peptides Piv--Pro--Abu-NHMe and Piv--Pro-Gpn-
OH, appear to correspond to two distinct conformational
families, which may be related to their counterparts in  ±
sequences. An important difference between the two  ± 
turns is that in Piv--Pro--Abu-NHMe, the pro-R hydrogen
of -Abu CH2CO group is involved in the intermolecular
interaction. In Piv--Pro-Gpn-OH, it is the pro-S hydrogen of
the Gpn CH2CO group. Figure 4b shows a superposition of
the structure of Piv--Pro-Gpn-OH with the type II -turn
conformation adopted by the peptide Piv--Pro-Aib-
NHMe.[15] Figure 4c shows the superposition of the structure
Piv--Pro--Abu-NHMe and the type I -turn conformation
observed in Piv-Pro-Thr-NHMe.[16] The excellent superposi-
tion of the  ± NH ¥ ¥ ¥O hydrogen bond stabilized -turn
Figure 3. A view of crystal packing in a) Piv-Pro-Gpn-OH (1), b) Boc-Gly-Gpn-OH (2), c) Boc-Aib-Gpn-OH (3), d) Boc-Aib-Gpn-OMe (4). The
intermolecular and intramolecular hydrogen bonds are shown as dotted lines.
Hybrid Peptides 4789±4795
Chem. Eur. J. 2003, 9, 4789 ± 4795 www.chemeurj.org ¹ 2003 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim 4793
Figure 4. a) Superposition of the structures of Piv-Pro-Gpn-OH (black)
and Piv-Pro--Abu-NHMe (gray; Pro71.0, Pro26.1, Abu
77.2, 1Abu -50.2, 2Abu172.2 and Abu 140.0).[7] b) Superposi-
tion of Piv-Pro-Gpn-OH (black) and Piv-Pro-Aib-NHMe[15] (gray; Pro
57.8, Pro 139.2, Aib 61.4 and Aib 25.1), RMSD 0.36 ä. c) Su-
perposition of Piv-Pro--Abu-NHMe (black) and Piv-Pro-Thr-NHMe[16]
(gray; Pro65.8, Pro21.8, Thr102.8 and Thr 6.5),
RMSD 0.26 ä. Only the backbone atoms are used for the superposition.
The C ¥ ¥ ¥O distances in the  ±  turn and the N ¥ ¥ ¥O distances in the  ±
turn are indicated. The representation was generated by using the program
MolMol.[25]
segments, and  ±  CH ¥ ¥ ¥O hydrogen bond stabilized chain
reversals is evident. Thus it appears possible to generate
mimetics of the common -turns type I and type II in  ± 
sequences. The oxy analogue of the -turn with an intra-
molecular 4 1 O ¥ ¥ ¥HO hydrogen bond has been observed
in an N-protected tripepide acid Z-(Aib)3-OH.[17]
In peptides Boc-Gly-Gpn-OH (2), Boc-Aib-Gpn-OH (3),
and Boc-Aib-Gpn-OMe (4) there are no apparent hydrogen
bond interactions; this restricts the torsional freedom at both
residues and stabilizes the observed chain reversal. Never-
theless, in all these  ±  sequences, a compact folded structure
is observed which brings the N- and the C-terminal groups
into close proximity.
Gabapentin conformations : Gabapentin is unique among the
-amino acid residues studied so far, in that, it is symmetri-
cally substituted at the central -carbon atom; this results in a
restricted range of accessible values of 1 and 2. In all four
structures, the observation of gauche,gauche (g,g) conforma-
tions with both the dihedral angles having the same sign,
suggests that this is undoubtedly an energetically preferred
structure for the Gpn residue. In all cases, the , values in
Gpn are semi-extended ( 	100,  	85). If all four
torsion angles are considered, the structures of peptides 1 to 4
reveal only two conformational families for the Gpn residue:
1)  98, 162, 273,  79 (mean values of 1
and 3), and 2) 103, 146, 249, 92
(mean values of 2 and 4). In case 1, an intramolecular nine-
membered OH ¥ ¥ ¥O hydrogen bond is formed between the
COof the preceding residue and the terminal carboxylic acid
OH group of the Gpn residue. In case 2, a short N ¥ ¥ ¥O
distance is observed between the Gpn NH and Gpn CO
groups (N ¥ ¥ ¥O 2.928 ä in 2 and N ¥ ¥ ¥O 2.957 ä in 4).
However, in both these cases the hydrogen bond angles
(Table 3) appear to lie on the borderline of the limits; this is
considered accepted for a stabilizing interaction.[18]
It is noteworthy that the two backbone conformational
families observed for the Gpn residue appear to favor distinct
orientation for the substitutents on the cyclohexane ring; in
peptides 1 and 3 the carboxymethyl group adopts an axial
position, while in peptides 2 and 4 the aminomethyl group is in
the axial position.
Conclusion
This study provides an accurate conformational character-
ization of the stereochemically constrained , disubstituted
-amino acid residue Gpn in four distinct peptide structures.
The Gpn residue appears to contribute to the generation of a
compact folded backbone conformation. This feature should
be valuable in peptide design. The search for new peptidomi-
metics and foldamers, which provide access to a range of novel
three- dimensional molecular structures, has been greatly
facilitated by the findings of Seebach and Gellman; they
found that peptides derived from -amino acid residues
provide an entry to conformational families, hitherto inacces-
sible for -amino acids.[19] The rapidly developing field of -
peptide conformations has also stimulated investigations on
- and -amino acid residues as novel elements in the design
of folded structures.[20] The enhanced proteolytic stability of -
and -peptides is a particularly attractive feature for analogue
design.[21] The use of hybrid sequences that incorporate both
- and -amino acids promises to greatly expand the
repertoire of mimics of biologically active peptides.[22] The
observation of a CH ¥ ¥ ¥O hydrogen-bond-mediated chain
reversal in Piv-Pro-Gpn-OH (1), which may serve as a -turn
surrogate, provides an entry to the design of a novel -turn
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mimetics in an  ±  peptide sequence. The possibility of
extending such chain reversals to nucleate hairpin structures
merits further investigation.[23] The structures of Boc-Gly-
Gpn-OH (2), Boc-Aib-Gpn-OH (3), and Boc-Aib-Gpn-OMe
(4) also suggest that Gpn residues may be used to generate
chain reversals that do not require strong intramolecular
hydrogen bonds for conformational stabilization.
Experimental Section
Gabapentin was the product of Hikal, Bangalore (India). Melting points
were determined by using a B¸chi melting point B-540 apparatus. 1H NMR
spectra were recorded on a Bruker AMX-400 MHz spectrometer by using
tetramethylsilane as an internal standard. Mass spectra were recorded on a
HP LCMSD 1100 electrospray mass spectrometer.
General procedure for the synthesis of peptides 1 ± 3 : A solution of H-Gpn-
OH (6 mmol, 1.02 g, dissolved in 15 ml of 10% Na2CO3) was added to a
stirred solution of N-protected N-hydroxy succinimide ester, Piv/Boc-AA-
OSu (5 mmol), in THF, (20 mL). This was then stirred for 12 h at room
temperature. After the reaction, THF was evaporated and the residue was
dissolved in water. The aqueous layer was cooled, the pH was adjusted to
2 by the addition of 1 HCl, and then extracted with ethyl acetate. The
pooled organic extracts were dried over Na2SO4, and after evaporation in
vacuo, the peptides were present as white crystalline solids. The peptides
were purified by medium-pressure liquid chromatography over a reverse-
phase C18 column (40 ± 60 m). The identity of the peptides were confirmed
by NMR spectroscopy (400 MHz) and electrospray mass spectrometry.
Piv--Pro-Gpn-OH (1): Yield: 82%; m.p. 109 ± 110 C; 1H NMR (CDCl3):
 1.26 (s, 9H; Piv CH3), 1.3 ± 1.5 (m, 10H; cyclohexyl), 1.9 ± 2.1 (m, 4H;
Pro CH2, CH2), 2.22, 2.29 (d, 2H; Gpn CH2), 3.17, 3.33 (dd, 2H; Gpn
CH2), 3.71 (m, 2H; Pro CH2), 4.63 (m, 1H; Pro CH), 7.23 ppm (s, 1H;
Gpn NH). MS: m/z cald: 352; found: 375.1 [MNa], 727.5 [2MNa].
Boc-Gly-Gpn-OH (2): Yield: 78%; m.p. 119 ± 120 C; 1H NMR (CDCl3)
 1.2 ± 1.6 ((m, 10H; cyclohexyl) and (s, 9H; Boc CH3)), 2.2 (s, 2H; Gpn
CH2), 3.3 (d, 2H; Gpn CH2), 3.8 (d, 2H; Gly CH2), 5.5 (s, 1H; Gly NH),
7.0 ppm (s, 1H; Gpn NH); MS: m/z cald: 328; found: 351 [MNa], 679.3
[2MNa].
Boc-Aib-Gpn-OH (3): Yield: 84%; m.p. 136 ± 137 C; 1H NMR (CDCl3):
 1.2 ± 1.5 ((m, 10H; cyclohexyl), (s, 6H; Aib CH3) and (s, 9H; Boc
CH3)), 2.27 (s, 2H; Gpn CH2), 3.22 (d, 2H; Gpn CH2), 5.05 (s, 1H; Aib
NH), 7.15 ppm (t, 1H; Gpn NH). MS:m/z cald: 356; found: 379 [MNa],
735.5 [2MNa].
Boc-Aib-Gpn-OMe (4): Boc-Aib-OH (0.40 g, 2 mmol) was dissolved in
THF (5 ml), 0.46 g (2 mmol) of Gpn-OMe obtained from its hydrochloride
was added followed by DCC (0.40 g, 2 mmol) and HOBt (0.270 g). The
mixture was stirred at room temperature for 12 h. The precipitated DCU
was filtered and the THF was evaporated. It was redissolved in EtOAc and
washed with HCl (1, Na2CO3 (1, and water. The solvent was then dried
over anhydrous Na2SO4 and evaporated in vacuo, to yield the peptide as
white crystalline solid. The peptide was purified by medium pressure liquid
chromatography over a reverse-phase C18 column (40 ± 60 m). The
identity of the peptide was confirmed by NMR spectroscopy (400 MHz)
and electrospray mass spectrometry. Yield: 82%; m.p. 109 ± 110 C;
1H NMR (CDCl3)  1.25 ± 1.6 ((m, 10H; cyclohexyl), (s, 6H; Aib CH3)
and (s, 9H; Boc CH3)), 2.3 (s, 2H; Gpn CH2), 3.25 (d, 2H; Gpn CH2), 3.65
(s, 3H; OCH3), 5.0 (s, 1H; Aib NH), 7.05 ppm (s, 1H; Gpn NH). MS: m/z
cald: 370; found: 393.2 [MNa], 763.5 [2MNa].
X-ray diffraction : Single crystals suitable for X-ray diffraction were
obtained by slow evaporation of concentrated solution of the mixture of
aqueous and organic solvents. Table 1 summarizes the crystallographic data
and other details for compounds 1 to 4. X-ray data were collected at room
temperature on a Bruker AXS SMART APEX CCD diffractometer, by
using MoK radiation (	 0.71073 ä). -scan type was used. Structures
were obtained by direct methods by using SHELXS-97.[24a] Refinement was
carried out against F 2 with the full-matrix least-squares methods by using
SHELXL-97.[24b] The hydrogen atoms were located from different Fourier
maps, except for the Piv group in peptide 1. The standard deviations in
bond lengths were approximately 0.004 ä and those of bond angles were
approximately 0.2. CCDC-200611 1, CCDC-208874 2, CCDC-208872 3,
and CCDC-208873 4 contains the supplementary crystallographic data for
this paper. These data can be obtained free of charge via www.ccdc.cam.a-
c.uk/conts/retrieving.html (or from the Cambridge Crystallographic Data
Centre, 12 Union Road, Cambridge CB21EZ, UK; fax: (44)1223-336-
033; or e-mail : deposit@ccdc.cam.ac.uk).
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